According to the Zhitong Finance App, Hengrui Pharmaceutical (600276.SH) announced that the company received approval from the China Drug Administration to issue a “Drug Clinical Trial Approval Notice” for acitoppa ethanolamine tablets and agreed to carry out clinical trials of combined cyclosporine (CsA) for the initial treatment of non-severe aplastic anemia (NSAA).

Hytrapopa ethanolamine tablets have been approved for marketing for two indications, namely: they were approved by the National Drug Administration in June 2021 for the treatment of adult patients with chronic primary immune thrombocytopenia who have not responded well to treatments such as glucocorticoids and immunoglobulins, and for the treatment of adult patients with severe aplastic anemia with poor efficacy of immunosuppressive treatment.